Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. (2020)
Attributed to:
A Programme for ALS Care in Europe (ALS-CarE)
funded by
ESRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2020.102844
PubMed Identifier: 32651161
Publication URI: http://europepmc.org/abstract/MED/32651161
Type: Journal Article/Review
Volume: 59
Parent Publication: EBioMedicine
ISSN: 2352-3964